•• Combination therapy of extended surgical operation and anti-cancer drugs against advanced colorectal and gastric cancer.Less invasive thoracoscopic/laparoscopic surgery for esophageal cancer, gastric cancer, colorectal cancer, hepatocellular•carcinoma, pancreatic tumor and other GI malignancies.Living donar liver transplantation and caderveric donor liver transplantation for chronic liver disease, acute liver failure andmetabolic disorder. • •• Hepatobiliary pancreatic surgeryChief：Associate Prof. Akira ShimizuMIA PaCa-2 parentMIA PaCa-2 drug resistanttreatment Electron micrograph showing increased mitochondrial mass after acquisition of anticancer drug resistanceInvolvement of mitochondria in the acquisition mechanism of anticancer drug resistance in pancreatic cancer cellsElucidation of the mechanism by which pancreatic cancer cells acquire resistance to anticancer drugs and development of drugs that nullify resistanceElucidation of immune responses in the microenvironment and development of therapeutic drugs through cell-to-cell communication analysis using MASLD model mice and single cell RNA sequencingFor hepato-biliary-pancreatic malignant diseases for which the treatment effectis insufficient with surgery or anti-tumor drugs alone, treatment results will beimproved by providing a new treatment option that combines these two.The combination of more efficient adjuvanttherapy and organ functionimprovement therapy enables aggressive surgical therapy and improves thesafety of surgery.Doctors can build careers as researchers in our lab or oversea study program,or as specialists in hepatobiliary pancreatic surgery in University Hospital, or asboard certified surgeons in gastroenterology in the affiliated hospitals. Summary of ActivityIn the first department of surgery, we conduct clinical practice and research into three groups of hepatobiliary pancreaticgroup, digestive tract group, transplant and pediatric surgery group.The main target of treatment are gastroenterological malignancies such as liver cancer, pancreas cancer, biliary tract cancer,esophageal cancer, gastric cancer and colorectal cancer. In addition to surgical treatment, comprehensive treatment such asdiagnosis and chemotherapy is the corresponding area.In transplantation and pediatric group, living donor liver transplantation and cadaveric donor liver transplantation for end-stageliver disease and some liver-related metabolic disease have been carried out with low mortality rate.Clinical research and basic research on digestive tract cancer, transplantation, regenerative medicine are also conducted.Please see the pages of each groups for details of research contents.Clinical SubjectImprovement of operative results in hepato-biliary pancreqatic malignancy.Division 1.Hepato-Biliary-Pancreatic surgery group2.Digestive tract surgery group3.Transplantation and pediatric surgery groupresection is the first choice ofSurgicalfor malignanthepatobiliary and pancreatic diseases, but there are many issues thatneed to be addressed. We are conducting research that will contributeto clinical medicine, such as elucidating the mechanism of anticancerdrug resistance acquisition by focusing on oxidative phosphorylation bymitochondria in cancer cells, identifying new biomarkers in the fibrosisprogression and carcinogenesis processes of MASLD.Research subjectOutlook for researchOutlook for students after graduation 17Transplantaion and Pediatric Surgery• Surgical treatment for various pediatric disease.SurgeryGastroenterologicalHepato-Biliary-PancreaticSurgeryRegenerative medicine and treatment of malignancy - bench to bedside - Surgical treatment for digestive tract cancer and liver transplantation for Intractable liver disease
元のページ ../index.html#22